Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: Early versus late diagnosis

Clinical Neuropharmacology

Volumn 36, Issue 3, 2013, Pages 78-83

  Yahalom, Gilad ^a,b   Tsabari, Rakefet ^b,c   Molshatzki, Noa ^c   Ephraty, Lilach ^a,b   Cohen, Hofit ^d,e   Hassin Baer, Sharon ^a,b,e  

^a Chaim Sheba   (Israel)

^b Sagol Neuroscience Center   (Israel)

^c Department of Neurology   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

cerebrotendinous xanthomatosis; chenodeoxycholic acid; Jewish Moroccan; prognosis

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTANOL;

ADULT; ARTICLE; CEREBROTENDINOUS XANTHOMATOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; LONG TERM EXPOSURE; MALE; MOBILIZATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CHENODEOXYCHOLIC ACID; CHOLESTANETRIOL 26-MONOOXYGENASE; CROSS-SECTIONAL STUDIES; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MUTATION; NERVOUS SYSTEM DISEASES; TIME FACTORS; TREATMENT OUTCOME; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 84878827771     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318288076a     Document Type: Article

References (18)

1. Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991;266:7779-7783.
2. Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004;27:42-50. Review.
3. Menkes JH, Schimschock JR, Swanson PD. Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 1968;19:47-53.
4. Leitersdorf E, Reshef A, Meiner V, et al. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest 1993;91: 2488-2496.
5. Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. In: Pagon RA, Bird TD, Dolan CR, et al, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2003.
6. Salen G, Berginer V, Shore V, et al. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med 1987;316:1233-1238.
7. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984;311:1649-1652.
8. Bonnot O, Fraidakis MJ, Lucanto R, et al. Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid. CNS Spectr 2010;15:231-236.
9. Van Heijst AF, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 1998;157:313-316.
10. Mondelli M, Sicurelli F, Scarpini C, et al. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci 2001;190:29-33.
11. Reshef A, Meiner V, Berginer VM, et al. Molecular genetics of cerebrotendinous xanthomatosis in Jews of North African origin. J Lipid Res 1994;35:478-483.
12. Leitersdorf E, Safadi R, Meiner V, et al. Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics. Am J Hum Genet 1994;55:907-915.
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
15. Berginer VM, Carmi R, Salen G. Pregnancy in women with cerebrotendinous xanthomatosis (CTX): high risk condition for fetus and newborn infant? Am J Med Genet 1988;31:11-16.
16. Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataract: think cerebrotendinous xanthomatosis and treat. Pediatrics 2009;123:143-147.
17. Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 2011;18:1203-1211. doi: 10.1111/j. 1468-1331.2011.03439.x. E-pub 2011 Jun 4. Review.
18. Mignarri A, Rossi S, Ballerini M, et al. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 2011;258:783-790.